Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Bellete Separation

On May 20, 2026, CG Oncology, Inc. (the "Company") and Ambaw Bellete, the Company's President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026. The Company thanks Mr. Bellete for his contributions and wishes him well in his next endeavors.

The Company expects to enter into a separation agreement with Mr. Bellete that provides for a general release and waiver of claims against the Company, and pursuant to which Mr. Bellete will receive the severance benefits set forth in Section 4(b) of his Amended and Restated Employment Agreement, effective January 9, 2025 and filed as Exhibit 10.12 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission ("SEC") on March 28, 2025.

The Company has initiated a search for a Chief Commercial Officer.

Kuan Appointment as President

On May 20, 2026, the Company's Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete's separation. Mr. Kuan's biographical information is set forth under the section titled "Election of Directors" in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities (File No. 333-290108), filed with the SEC on April 24, 2026, and is incorporated herein by reference.